ClinicalTrials.gg
Active, not recruitingNCT06118411Viti-UpUpdated Jun 9, 2026

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

A Phase 3 interventional study of Upadacitinib and Placebo in Vitiligo, sponsored by AbbVie. Active, not recruiting at 148 sites in 19 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
614
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Vitiligo with a site in United States — 14 open to participants now, 24 under way, 7 of them phase 3. Vitiligo · United States.

Enrollment
2nd of 68
614 · median 37
Started
2023
with 9 others
Phase 3
12 of 80
1 open now
Primary completion
2028-03
later than 16 of 23 live
Registered
66th of 80
by date
Lead sponsor
2 of 80
AbbVie

Among the 80 studies in Vitiligo with a site in United States, this one is the 2nd largest by enrollment of the 68 interventional ones that give a count, is one of 10 that started in 2023, is one of 12 in phase 3, reaches primary completion later than 16 of the 23 other live ones, and was the 66th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

14 of the 80 studies in Vitiligo with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Vitiligo with a site in United States, or all of them as a file.
02

Study summary

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo (NSV). Adverse effects and change in disease activity will be assessed.

Upadacitinib is currently being investigated for the treatment of NSV. There will be 2 replicate studies running at the same time (Study 1 and Study 2 with periods A and B), an optional exploratory NB-UVB phototherapy study (Study 3), and a re-randomized dose-escalation study (Study 4). In Period A, participants are placed in 1 of 2 groups called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will receive placebo. In Period B, all participants will receive upadacitinib. Approximately 540 adult and adolescent participants with NSV will be enrolled between each main study at around 180 sites worldwide with an option for adult participants who completed Period A of either study and did not achieve T-VASI90 at week 48 while on study drug, to enter Study 3. Participants who failed to achieve T-VASI75 response at week 118 of Study 1 or 2 or at week 70 of Study 3 will be considered for entry into Study 4.

In Studies 1 and 2: Period A, participants will receive oral tablets of upadacitinib or placebo once a day for 48 weeks. In Period B, participants will receive oral tablets of upadacitinib 15 mg once a day for 112 weeks. Participants will be followed up for 30 days. Study 3 participants will receive upadacitinib monotherapy or upadacitinib with Narrow-Band Ultraviolet B (NB-UBV) phototherapy for at least 24 weeks followed by upadacitinib alone. In Study 4, participants will be re-randomized to receive oral tablets of upadacitinib 15 mg or 30 mg once a day for 56 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Vitiligo

Browse trials for

Keywords

  • Vitiligo
  • Non-Segmented Vitiligo
  • Viti-Up
  • Upadacitinib
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented clinical diagnosis of non-segmented vitiligo (NSV).
  • At Screening and Baseline Visits, participants must satisfy at least 1 of the following criteria:

    • >= 0.5 F-VASI and 5 \<= T-VASI \< 50 AND have failed at least 1 topical and/or at least 1 topical calcineurin inhibitor for vitiligo; or
    • >= 0.5 F-VASI and 5 \<= T-VASI \< 50 AND have a sign of actively progressing vitiligo; or
    • >= 0.5 F-VASI and 10 \<= T-VASI \< 50.

Exclusion criteria

Exclusion Criteria:

  • Segmental or localized vitiligo.
  • History of active skin disease other than vitiligo that could interfere with the assessment of vitiligo.
  • >33% leukotrichia in areas of vitiligo on the face or > 33% leukotrichia in areas of vitiligo on the body (including the face).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
614 participants (actual)

Study arms

  • Experimental
    Study 1, Period A: Group 1

    Participants will receive upadacitinib 15 mg once daily for 48 weeks.

    Drug: Upadacitinib

  • Placebo comparator
    Study 1, Period A: Group 2

    Participants will receive placebo once daily for 48 weeks.

    Drug: Placebo

  • Experimental
    Study 2, Period A: Group 1

    Participants will receive upadacitinib 15 mg once daily for 48 weeks.

    Drug: Upadacitinib

  • Placebo comparator
    Study 2, Period A: Group 2

    Participants will receive placebo once daily for 48 weeks.

    Drug: Placebo

  • Experimental
    Study 1, Period B: Group 1 Open-Label Extension Period

    Participants that were randomized to receive upadacitinib in Period A Group 1, will continue to receive upadacitinib 15 mg once daily for 112 weeks in Period B.

    Drug: Upadacitinib

  • Experimental
    Study 1, Period B: Group 2 Open-Label Extension Period

    Participants that were randomized to receive placebo in Period A Group 2, will receive upadacitinib 15 mg once daily for 112 weeks in Period B.

    Drug: Upadacitinib

  • Experimental
    Study 2, Period B: Group 1 Open-Label Extension Period

    Participants that were randomized to receive upadacitinib in Period A Group 1, will continue to receive upadacitinib 15 mg once daily for 112 weeks in Period B.

    Drug: Upadacitinib

  • Experimental
    Study 2, Period B: Group 2 Open-Label Extension Period

    Participants that were randomized to receive placebo in Period A Group 2, will receive upadacitinib 15 mg once daily for 112 weeks in Period B.

    Drug: Upadacitinib

  • Experimental
    (Optional) Study 3: Open Label Upadacitinib

    Participants will receive upadacitinib 15 mg once daily for 112 weeks.

    Drug: Upadacitinib · Other: NB-UVB (narrow-band ultraviolet B) Phototherapy

  • Experimental
    (Optional) Study 3: Open Label Upadacitinib + NB-UVB

    Participants will receive 15 mg upadacitinib once daily for 112 weeks and Narrow-band ultraviolet B (NB-UVB) for up to 28 weeks.

    Drug: Upadacitinib · Other: NB-UVB (narrow-band ultraviolet B) Phototherapy

  • Experimental
    Study 4: Upadacitinib 15 mg

    Eligible participants will be re-randomized to receive upadacitinib 15 mg once daily for 56 weeks.

    Drug: Upadacitinib

  • Experimental
    Study 4: Upadacitinib 30 mg

    Eligible participants will be re-randomized to receive upadacitinib 30 mg once daily for 56 weeks.

    Drug: Upadacitinib

Interventions

  • Oral Tablets

    Also known as: ABT-494, Rinvoq

  • DrugPlacebo

    Oral Tablets

  • OtherNB-UVB (narrow-band ultraviolet B) Phototherapy

    NB-UVB phototherapy is a commonly used treatment modality in participants with vitiligo and can be administered in an office setting or at home 2 times per week

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Total Vitiligo Area Scoring Index (T-VASI) 50 (≥ 50% Improvement in T-VASI From Baseline)

    The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area \[BSA\]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100.

    Time frame: Week 48

  2. Percentage of Participants Achieving Facial-Vitiligo Area Scoring Index (F-VASI) 75 (≥ 75% Improvement in F-VASI From Baseline)

    The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.

    Time frame: Week 48

  3. Percentage of Participants Achieving T-VASI 75 (≥ 75% Improvement in T-VASI From Baseline)

    The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area \[BSA\]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100.

    Time frame: Study 4 Week 28

  4. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately Week 175

Secondary outcomes

  1. Percentage of Participants Achieving F-VASI 50 (≥ 50% Improvement in F-VASI From Baseline)

    The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.

    Time frame: Week 48

  2. Percentage of Participants Achieving F-VASI 75 (≥ 75% Improvement in F-VASI From Baseline)

    The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.

    Time frame: Week 24

  3. Percent Change from Baseline in F-VASI

    The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.

    Time frame: Week 24

  4. Percent Change from Baseline in T-VASI

    The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area \[BSA\]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100.

    Time frame: Week 48

  5. Percentage of Participants Achieving F-VASI 90 (≥ 90% Improvement in F-VASI From Baseline)

    The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.

    Time frame: Week 48

  6. Percentage of Participants Achieving T-VASI 75 (≥ 75% Improvement in T-VASI From Baseline)

    The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area \[BSA\]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100.

    Time frame: Week 48

  7. Percentage of Participants Achieving 3D Imaging Facial Vitiligo 40 (≥ 40% Reduction in Facial Vitiligo Area Measured by 3D Digital Imaging from Baseline) (Study 1 Only)

    3D imaging will be used to objectively quantify the facial vitiligo area.

    Time frame: Week 48

  8. Percentage of Participants Achieving No Increase from Baseline in T-VASI Among Participants with Actively Progressing Vitiligo at Baseline

    The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area \[BSA\]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100.

    Time frame: Up to Approximately Week 12

  9. EU/EMA Only: Percentage of Participants Achieving a Physician's Global Impression of Change - Vitiligo (PhGIC-V) of "Much better (1)"

    The physician rates the overall change in the patients vitiligo by comparing the severity of vitiligo right now with the severity of vitiligo since the subject started the study treatment. Responses range from 1 = "Much better" to 5 = "Much worse."

    Time frame: Week 48

  10. EU/EMA Only: Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) score of "A lot less noticeable (4)" or "No longer noticeable (5)"

    The VNS is a single-item, validated questionnaire used in clinical trials to assess the noticeability of vitiligo lesions following therapy. The item is scored on a 5-point scale: 1 = more noticeable; 2 = as noticeable; 3 = slightly less noticeable; 4 = a lot less noticeable; and 5 = no longer noticeable. A score of 4 or 5 represents treatment success

    Time frame: Week 48

  11. EU/EMA Only: Percentage of Participants Achieving a Patient's Global Impression of Change-Vitiligo (PaGIC-V) of "Much better (1)"

    The PaGIC-V asks participants to rate the overall change in their vitiligo by comparing the severity of their vitiligo right now with the severity of their vitiligo since they started the study treatment. Responses range from 1 = "Much better" to 5 = "Much worse."

    Time frame: Week 48

07

Study locations

148 sites

Showing the first 100 of 148 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Mar 2028, 51 months after the start.

Of 18 phase 3 interventional studies under Vitiligo, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 44. This study's planned 51 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2023
First posted
Nov 7, 2023
StartActual
Dec 19, 2023
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06118411
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
Dec 19, 2023
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Jun 9, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion